You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for New Drug Application (NDA): 206039

✉ Email this page to a colleague

« Back to Dashboard

NDA 206039 describes MAGNESIUM SULFATE, which is a drug marketed by B Braun Medical, Aspiro, Exela Pharma, Fresenius Kabi Usa, Hospira, Baxter Hlthcare Corp, Hq Spclt Pharma, Pharmobedient, Amneal, Gland, Milla Pharms, and Mylan Labs Ltd, and is included in twenty NDAs. It is available from ten suppliers. Additional details are available on the MAGNESIUM SULFATE profile page.

The generic ingredient in MAGNESIUM SULFATE is magnesium sulfate. There are one hundred and forty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the magnesium sulfate profile page.

Summary for 206039

Tradename:	MAGNESIUM SULFATE
Applicant:	Exela Pharma
Ingredient:	magnesium sulfate
Patents:	0

Medical Subject Heading (MeSH) Categories for 206039

Analgesics
Anesthetics
Anti-Arrhythmia Agents
Anticonvulsants
Calcium Channel Blockers
Tocolytic Agents

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAMUSCULAR, INTRAVENOUS			Strength	5GM/10ML (500MG/ML)
Approval Date:	Dec 18, 2014	TE:		RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.